On April 3, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, reported a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR) inhibitor (e.g. osimertinib) (Press release, Mirati, APR 3, 2023, View Source [SID1234629766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Findings will be presented on April 17 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2023) Annual Congress as an oral presentation at 3:36 p.m. -3:51 p.m. ET / 12:36 p.m.- 12:51 p.m. PT (Presentation #3499) during the Molecular Pathway Discovery and Translation in Solid Tumors mini session. The full abstract for the presentation can be found here.

In addition, Mirati will share poster presentations featuring MRTX1719, the company’s novel MTA cooperative PRMT5 inhibitor. These posters highlight the mechanism by which MRTX1719 elicits potent and selective synthetic lethality in MTAP deleted tumors as well as the further enhancement of antitumor activity via rational targeted combination strategies (Posters #2778/1 and 2779/2). Posters can be viewed on April 17 from 1:30 p.m. – 5:00 p.m. ET/ 10:30 a.m. – 2:00 p.m. PT during the Experimental and Molecular Therapeutics Session and will be available here.